7th Gene Therapy Analytical Development Summit 2025

As gene therapies evolve beyond AAV to include mRNA, CRISPR-based platforms, and novel capsids, analytical strategies must advance in parallel to meet rising complexity and regulatory expectations. With increased pressure for analytical rigor, potency relevance, and product consistency, the need for robust, forward-thinking solutions is more urgent than ever.

The 7th Gene Therapy Analytical Development Summit returns to Boston this October as the industry’s most comprehensive event dedicated to analytical excellence across the gene therapy development lifecycle-from early research through to BLA submission and commercial readiness.


Speakers: Anthony Blaszczyk, Senior Scientist, U.S. Pharmacopeia, Athea Vichas, Senior Principal Scientist, Bristol Myers Squibb, Brooke Brown, Principal Scientist, Novartis AG, Chynna Broxton, Analytical Development Scientist, Spark Therapeutics, Inc., Crystal Bryan, Associate Director - Quality Control and Analytical Technologies, Editas Medicine, Damon Barbacci, Director - Analytical Development, Genentech, Debojit Bose, Principal Scientist, Regeneron Pharmaceuticals, Haiqing Yu, Senior Scientist and Team Manager - Analytical Development and Quality Control, Sanofi, Jeanette Young, Director for cell and gene therapy method and Tech transfer, Astellas Pharma, Jimmy Zhong, Scientist, Tessera Therapeutics, Johnson Varghese, Vice President - Analytical Sciences and Development, Beam Therapeutics Inc., Kan Zhu, Director, CSL, Luis Rascon, Senior Associate - Research and Analytical Development, Astellas Pharma, Margaret Butko, Director - Assay Development, Chemistry, Manufacturing and Controls, Adverum, Marina Feschenko, Head of Analytical and Formulation Drug Product Sciences, Voyager Therapeutics, Inc, Prateek Tripathi, Senior Expert - Science and Technology, Novartis AG, Rishi Kothari, Process Development Engineer, Regeneron Pharmaceuticals, Sarah Tuller, CRO, Opus Genetics, Scott Jeffers, Chief Technology Officer, GenSight Biologics, Sue Duan, Head of Analytical Development, Astellas Pharma, Suman Jangid, Director - Global Regulatory Chemistry, Manufacturing, Controls and Gene Therapy, BridgeBio Pharma, Inc., Susan Tam, Quality Control Analyst, Astellas Pharma, Susumu Uchiyama, Professor, Osaka University, T.J. Craddick, Head of Genome Editing, CRISPR Therapeutics, Tyler Lindgren, Associate Scientist II, BridgeBio Pharma, Inc., Uditha DeAlwis, Vice President - Analytical Development and Quality Control, Sarepta Therapeutics, Vanessa Strings-Ufombah, Executive Director, CMC Assay and Drug Product Development, Adverum Biotechnologies, Wei Zhang, Director - Chemistry Manufacturing and Controls Leader, Ultragenyx Pharmaceutical Inc, Wesley Jackson, Senior Principal Biophysical Chemist, Eli Lilly and Co., Win Cheung, Senior Director - Analytical Development, REGENXBIO